secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2024-06-12T23:59:59+00:00
Accession:  0001213900-24-051891
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics stockholders approve 2024 equity plans; amended employment agreements for CEO and other executives
--------------------------------------------------------------------------------

- Stockholders voted 10.3M for, 95K against to approve 2024 Equity Incentive Plan.
- Stockholders voted 10.4M for, 12K against to approve 2024 Employee Stock Purchase Plan.
- CEO Martell's annual salary remains $727,272; target bonus 50% of base; severance 18 months base plus COBRA.
- CFO Cross salary $476,100; COO Mahal $481,301; CMO Tucker $514,500; each target bonus 45% of base.
- Company terminated prior severance plan in favor of individual employment agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024051891/0001213900-24-051891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024051891/ea0207631-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-051891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer